Intrahepatic microRNA expression and response to peginterferon-α and ribavirin therapy in patients with chronic hepatitis C

慢性丙型肝炎患者肝内 microRNA 表达及对聚乙二醇干扰素-α 和利巴韦林治疗的反应

• 批准号: 21590856
• 负责人: ENOMOTO Masaru
• 金额: $ 2.91万
• 依托单位: Osaka City University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2009
• 资助国家: 日本
• 起止时间: 2009 至 2011
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-21590856/
• 关键词: C型慢性肝炎; マイクロRNA; インターフェロン; リバビリン

The regulated microRNAs(miRNAs) in human livers infected with hepatitis C virus(HCV) were identified by microarray analysis. MiR-422a was down-regulated, and miR-199a-5p/199a-3p and miR-221/222 up-regulated in the human liver in a fibrosis progression-dependent manner. Their expression was validated by real-time RT-PCR. Among these miRNAs, miR-222 increased in mouse livers from two fibrosis models. The expression of miR-222 was up-regulated in cultured stellate cells LX-2 and increased during the course of culture-dependent activation of mouse primary stellate cells. NF-κB inhibitor significantly suppressed the miR-222 induction that was stimulated in culture by TNF-α or TGF-α. Although over-expression or down-regulation of miR-222 failed to regulate the growth of LX-2 cells, miR-222 bound to the p27^<Kip1> 3'UTR and regulated the expression of the corresponding protein. Transient transfection with miR-222 precursors significantly up-regulated α1(I) collagen and down-regulated MMP-1 mRNA expressions. In conclusion, miR-222 may be new markers for stellate cell activation and liver fibrosis progression.

应用基因芯片技术对丙型肝炎病毒（HCV）感染的人肝组织中受调控的microRNA（miRNAs）进行鉴定。miR-422 a在人肝脏中下调，miR-199 a-5 p/199 a-3 p和miR-221/222以纤维化进展依赖性方式上调。通过实时定量RT-PCR验证其表达。在这些miRNA中，miR-222在两种纤维化模型的小鼠肝脏中增加。miR-222的表达在培养的星形细胞LX-2中上调，并且在小鼠原代星形细胞的培养依赖性活化过程中增加。NF-κB抑制剂显著抑制TNF-α或TGF-α刺激的miR-222诱导。虽然过表达或下调miR-222不能调节LX-2细胞的生长，但miR-222与p27^<Kip1>3 'UTR结合并调节相应蛋白的表达。瞬时转染miR-222前体显著上调α1（I）胶原蛋白表达，下调MMP-1 mRNA表达。总之，miR-222可能是星状细胞活化和肝纤维化进展的新标志物。

项目成果

High prevalence of hepatitis C virus infection in Airin district, Osaka, Japan : A hospital-based study of 1162 patients

日本大阪爱林区丙型肝炎病毒感染率高：一项针对 1162 名患者的医院研究

• DOI: 10.1111/j.1872-034x.2011.00834.x
• 发表时间: 2011
• 期刊: Repatol Res
• 作者: Yamaguchi Y;Enomoto M;Fujii H;Tamori A;Sakaguchi H;Tanigawa T;Watanabe K;Fujiwara Y;Arakawa T;Harihara S;Monna T;Kawada N
• 通讯作者: Kawada N

Genotype 1bのC型慢性肝炎に対するPEG-IFN-α/リバビリン投与期間の個別化について:リアルタイムPCRによるresponse-guided therapyの再評価

基因型 1b 慢性丙型肝炎的 PEG-IFN-α/利巴韦林给药周期个体化：使用实时 PCR 重新评估反应引导治疗

• 发表时间: 2009
• 作者: 中屋美香;榎本大;林健博;遠山まどか;藤井英樹;小林佐和子;岩井秀司;森川浩安;田守昭博;坂口浩樹;羽生大記;塩見進;河田則文
• 通讯作者: 河田則文

Response-guided therapy for patients with chronic hepatitis who have high viral loads of hepatitis C virus genotype 2

对丙型肝炎病毒基因型 2 病毒载量较高的慢性肝炎患者进行反应指导治疗

• DOI: 10.1111/j.1872-034x.2011.00956.x
• 发表时间: 2012
• 期刊: Hepatol Res
• 影响因子: 4.2
• 作者: Yamaguchi Y;Tamori A;Tanaka Y;Iwai S;Kobayashi S;Fujii H;Morikawa H;Hagihara A;Enomoto M;Kawada N
• 通讯作者: Kawada N

Mosapride Citrate on Gastric Emptying in Interferon-Induced Gastroparesis

枸橼酸莫沙必利对干扰素引起的胃轻瘫胃排空的影响

• 发表时间: 2012
• 期刊: Dig Dis Sci
• 作者: Kawamura E;Enomoto M;Kotani K;Hagihara A;Fujii H;Kobayashi S;Iwai S;Morikawa H;Kawabe J;Tominaga K;Tamori A;Shiomi S;Kawada N
• 通讯作者: Kawada N

Could trastuzumab suppress hepatitis C virus in a patient with chronic hepatitis and breast cancer?

曲妥珠单抗能否抑制患有慢性肝炎和乳腺癌的患者的丙型肝炎病毒？

• 发表时间: 2011
• 期刊: Am J Gastroenterol
• 影响因子: 9.8
• 作者: Tamori A;Kawajiri H;Takashima T;Motoyama H;Morikawa H;Enomoto M;Hirakawa K;Kawada N
• 通讯作者: Kawada N